

MEDIA RELEASE 17 March 2022

AGREEMENT REACHED ON FUNDING REFORMS FOR MEDICAL DEVICES

The Medical Technology Association of Australia (MTAA) has signed a joint four-year agreement with the Commonwealth Government laying the foundation for the future of the Prostheses List.

The four-year agreement, signed between Minister for Health, the Hon. Greg Hunt MP, on behalf of the Commonwealth, and MTAA's Chair, Maurice Ben-Mayor, is the culmination of more than 12 months of intensive stakeholder negotiation and years of work to retain the Prostheses List and protect patient access and doctor choice in Australia's private health system.

The four-year agreement outlines the Commonwealth's iron clad commitments to the key policy parameters of the Prostheses List reforms, including:

- The continued funding of vital services for Cardiac Implantable Electronic Devices (such as pacemakers) for the next 12 months until a review of how to fund these services is completed,
- A 40/20/20 phased reduction of benefits for devices with a benefit level of more than 7 percent above prices in the public system, and
- Co-designed modernised pathways for new Prostheses List listings to ensure faster patient access to innovative new technologies.

MTAA Chair, Maurice Ben-Mayor, said the MedTech industry thanked Minister Hunt and his Office for ensuring the agreement's focus on recognising the explicit distinction between the public and private markets that still guarantees patient access and doctor choice.

"During this challenging time for the health sector it was encouraging to have Minister Hunt lead the reforms away from abolishing the Prostheses List and towards a process that would provide greater certainty for the MedTech industry," Mr Ben-Mayor said.

The Government's measures will lead to significant cuts being passed on as savings to private health insurance companies by way of more than \$900 million delivered by the MedTech industry.

MTAA CEO, Ian Burgess, said the total cuts incurred by the Australian MedTech industry of more than \$2 billion over eight years, is in stark contrast to the \$2.4 billion profits corporate health insurance companies have raked in over the last two years alone.

"While the four-year agreement provides a degree of certainty for Australian MedTech, there's still far more needing to be done to ensure insurer savings from these cuts are passed on to patients in the form of lower actual premiums. MTAA is keen to continue to work with the Commonwealth and key stakeholders to ensure the final reform package benefits patients and not just the insurance companies' bottom line," Mr Burgess said. "We expect Government to ensure the enormous sacrifices of Australian MedTech companies – who played a vital role in saving lives during the pandemic – aren't in vain. Insurers must be forced to tighten their own belt, cut their multi-million dollar 'management fees' and exorbitant executive benefits so that Australian families receive the full benefit of these cuts as guaranteed premium declines and faster access to new and innovative technologies."

MTAA believes that while these reforms will still place a significant burden on the MedTech industry, they're far better than the devastating changes the private health insurance industry had been lobbying for which would have seen doctor choice and patient access to life-saving medical devices severely restricted or even abolished.

"Achieving the key foundations of the reforms wouldn't have been possible without the continued and tireless work of stakeholders, including the Australian Private Hospitals Association (APHA), Catholic Health Australia (CHA), the Consumer Health Forum (CHF) and doctor groups – their contribution has helped set the positive direction for the future of the PL reforms," Mr Ben-Mayor said.

ENDS

Media contact: (02) 9900 0600 | media@mtaa.org.au

Did you know?

- Unlike most other areas of health care, medical devices prices have actually decreased over the past five years.
- While the cost per medical device is falling, the number of Australians needing devices is growing, due to population ageing, increased rates of chronic health conditions and the introduction of new technology.
- Medical devices make up less than 10 per cent of private health insurance costs and are not responsible for high private health insurance premiums.
- The medical technology sector has delivered over \$1.2 billion in savings on the Protheses List over the last 4 years.
- The medical device industry has been the sole contributor to reducing the pressure on private health insurance premium increases.
- Devices are the only part of our health system that have not been steadily increasing in price over the past two decades. Since 2005, on average, benefits for devices have decreased.
- In contrast to the MedTech sector, insurers costs are rising at a faster rate than CPI, AWE and general health inflation.
- Insurers made record profits in 2020 due to the COVID pause in elective surgery.
- Recent data from the Australian Prudential Regulation Authority (APRA), shows that insurers made their highest ever profits of \$1.8 billion in the last twelve months a 212% increase on their previous years' profits.
- APRA data also shows that between 2014-15 and 2020-21, corporate insurers increased their 'management expenses' from \$1.7 billion to \$2.5 billion an increase of over \$800 million¹,"
- Devices save lives every day in Australian hospitals and are an extremely cost-effective component of the Australian health system.

About MTAA

The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry. MTAA aims to ensure the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community.

MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. The range of medical technology is diverse with products ranging from familiar items such as syringes and wound dressings, through to high-technology implanted devices such as pacemakers, defibrillators, hip and other orthopaedic implants. Products also include hospital and diagnostic imaging equipment such as ultrasounds and magnetic resonance imaging machines.

MTAA members distribute the majority of the non-pharmaceutical products used in the diagnosis and treatment of disease and disability in Australia. Our member companies also play a vital role in providing healthcare professionals with essential education and training to ensure safe and effective use of medical technology.

¹ <u>https://www.apra.gov.au/sites/default/files/2021-</u>

^{11/}Quarterly%20private%20health%20insurance%20statistics%20highlights%20September%202021.pdf